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Updateon fertility preservation from the
Barcelona International Society for
Fertility Preservation–ESHRE–ASRM
2015 expert meeting: indications,
results and future perspectives
Francisca Martinez, on behalf of the International Society for Fertility Preservation–ESHRE–ASRM Expert
Working Group
Hospital Universitario Dexeus, Gran Via Carlos III, 71-75, 08208, Barcelona, SpainStudy Question: What progress has been made in fertility preservation (FP) over the last decade?
Summary Answer: FP techniques have been widely adopted over the last decade and therefore the establishment of international
registries on their short- and long-term outcomes is strongly recommended.
What Is Known Already: FP is a fundamental issue for both males and females whose future fertility may be compromised. Reproduc-
tive capacity may be seriously affected by age, different medical conditions and also by treatments, especially those with gonadal
toxicity. There is general consensus on the need to provide counselling about currently available FP options to all individuals wishing
to preserve their fertility.
Study Design, Size, Duration: An international meeting with representatives from expert scientiﬁc societies involved in FPwas held in
Barcelona, Spain, in June 2015.
Participants/Materials, Setting, Methods: Twenty international FP experts belonging to the American Society of Reproductive
Medicine, ESHRE and the International Society of Fertility Preservation reviewed the literature up to June 2015 to be discussed at
the meeting, and approved the ﬁnal manuscript. At the time this manuscript was being written, new evidence considered relevant
for the debated topics was published, and was consequently included.
Main Results and the Role of Chance: Several oncological andnon-oncological diseasesmayaffect current or future fertility, either caused
by the disease itself or the gonadotoxic treatment, andneed an adequate FP approach.Womenwishing to postponematernity and transgender
individuals before starting hormone therapy or undergoing surgery to remove/alter their reproductive organs should also be counselled
accordingly. Embryo and oocyte cryopreservation are ﬁrst-line FP methods in postpubertal women. Metaphase II oocyte cryopreservation
(vitriﬁcation) is the preferred option. Cumulative evidence of restoration of ovarian function and spontaneous pregnancies after ART
following orthotopic transplantation of cryopreserved ovarian tissue supports its future consideration as an open clinical application.
Semen cryopreservation is the only established method for FP in men. Testicular tissue cryopreservation should be recommended in pre-
pubertal boys even though fertility restoration strategies by autotransplantation of cryopreserved testicular tissue have not yet been tested
for safe clinical use in humans. The establishment of international registries on the short- and long-term outcomes of FP techniques is
strongly recommended.
Limitations, Reasons for Caution: Given the lack of studies in large cohorts or with a randomized design, the level of evidence for most
of the evidence reviewed was 3 or below.
Wider Implications of the Findings: Further high quality studies are needed to study the long-term outcomes of FP techniques.
Study Funding/Competing Interest(s): None.
Trial Registration Number: N/A. (Fertil Steril 2017;108:407-15. 2017 The Authors. Published by Elsevier Inc. on behalf of the
American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).)
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ASRM PAGESINTRODUCTION
Reproductive capacity may be seriously affected by age,
different conditions, including genetic syndromes, and also
by treatments, especially those with gonadal toxicity. Fertility
preservation (FP) is a fundamental issue for individuals of
reproductive age (both male and female) or prepubescent
boys and girls whose future fertility may be compromised.
There is general consensus on the need to provide counselling
about currently available FP options to all individuals
wishing to preserve their fertility. Timely referral to a fertility
specialist for informed FP decisions becomes essential.
Several techniques for FP are nowadays well established
while others are still considered experimental. These tech-
niques have been subject of continuous review by experts.
Reviews have been mostly focused on FP and cancer.
However, the need for FP in other pathologic situations, either
due to the disease itself or to gonadotoxic treatment, and even
in non-medical indications, is on the rise. Moreover, new per-
spectives to tackle FP are being developed, and evidence
about the results of spontaneous pregnancy and ART after
current FP procedures is growing. With the aim of reviewing
all these aspects and drawing recommendations, an interna-
tional meeting with representatives from expert scientiﬁc so-
cieties involved in FP was held in Barcelona (Spain) in June
2015. This paper summarizes the topics debated, with a spe-
cial focus on indications for FP, current outcomes and future
perspectives. A more detailed summary can be found at
Fertility and Sterility online.MATERIALS AND METHODS
Twenty international FP experts belonging to the American
Society of Reproductive Medicine (ASRM), European Society
of Human Reproduction and Embryology (ESHRE) and the In-
ternational Society of Fertility Preservation (ISFP) attended
the meeting. Experts conducted a review of the literature up
to June 2015 to be discussed at the meeting. At the time
this manuscript was being written, new evidence considered
relevant for the debated topics was published, and has
consequently been included. Given the lack of studies in large
cohorts or with a randomized design, the quality of evidence,
according to the European Society for Medical Oncology
Clinical Practice Guidelines for fertility preservation in cancer
patients (1) for most of the evidence reviewed was 3 or below.INDICATIONS FOR FP
Cancer
Many forms of cancer are associated with impaired semen
quality or ovarian function at the time of cancer diagnosis.
However, the main effect on fertility arises from commonly
used treatments such as chemotherapy with alkylating agents
and pelvic radiation. Gonadal failure resulting from these
treatments may affect different aspects of reproductive
health, including pubertal development, hormone production,
and sexual function in adults (2). More than 80% of children
and adolescents with cancer become long-term survivors (3),
raising the interest in the long-term effects of cancer treat-
ment on fertility.408Male. Spermatogonia are especially sensitive to chemo-
therapy and radiotherapy. The effect, which is dose-
dependent, may not be permanent if the spermatogonial
stem cell (SSC) population is not fully depleted. Data on the
impact of recent biological or targeted cancer therapies on
male fertility is limited (4). For most of these therapies, the ef-
fects seem to be mild, mostly involving reproductive endocri-
nology. Finally, surgical pelvic interventions for malignant or
benign disease may affect the anatomy or normal functioning
of reproductive organs.
Female. Chemotherapy and radiotherapy may induce prema-
ture ovarian insufﬁciency (POI) in women. Ovarian damage is
drug- and dose- dependent and increases as the patient ages
(5). Radiotherapy may also affect the uterus, leading to
reduced vascularity, myometrium damage (ﬁbrosis) and hor-
mone- dependent insufﬁciency. Data on the impact of recent
biological or targeted cancer female fertility therapies is also
limited except for bevacizumab, with a rate of 34% POI
reported (4). Fertility may also be impaired by surgical
removal or damage to reproductive organs.Non-oncological Medical Indications
FP options should also be discussed with adult and younger
women and men affected by several non-oncological medical
conditions. Table 1 summarizes the most common non-
oncological conditions requiring FP.
Autoimmune diseases. Table 2 summarizes autoimmune
diseases reported to beneﬁt from immunosuppressive therapy
with alkylating agents (cyclophosphamide). Continuous POI
in women with chronic autoimmune diseases also increases
the risk of hypoestrogenism-related comorbidities (23). Males
with systemic lupus erythematosus show a high frequency of
testicular Sertoli cell dysfunction (24). New treatment
approaches are changing the prognosis of patients with auto-
immune diseases, although information about toxicity for
reproduction is still limited.
Hematopoietic stem cell transplantation. Hematopoietic
stem cell transplantation (HSCT, autologous or allogeneic)
has been an important therapeutic tool for some oncological
and non- oncological systemic diseases. Patients undergoing
HSCT are at particularly high risk of developing ovarian (64–
85%) or testicular (50–90%) failure since aggressive chemo-
therapy and radiotherapy is needed to destroy pre- existing
bone marrow (8) (Table 1).
Medical conditions causing POI. POImay result from several
causes, either due to their extensive or progressive nature, or
bilateral adnexectomy (10, 11). Patients at risk of POI by a
known genetic cause or family history (Turner's syndrome,
fragile X mental retardation (FMR)1 pre-mutation, classic gal-
actosaemia) may also beneﬁt from FP (9). Women of reproduc-
tive agewith endometriosismay beneﬁt fromFPbefore surgical
treatment as they are at increased risk of POI and infertility (15).
Male genetic disorders and testicular tissue damage. Kline-
felter's syndrome is the most common sex chromosomal disor-
der in humans, causing hypogonadism and azoospermia in
>90% cases (6), and the beneﬁt of FP is currently unclear.VOL. 108 NO. 3 / SEPTEMBER 2017
TABLE 1
Non-oncological conditions requiring fertility preservation.
Indication Disease
Autoimmune diseases (6, 7) Systemic lupus erythematosus (SLE)
Behcet's disease
Churg-Strauss syndrome (eosinophilic granulomatosis)
Steroid resistant glomerulonephritis
Granulomatosis with polyangiitis (formerly Wegener's granulomatosis)
Inﬂammatory bowel diseases
Rheumatoid arthritis Pemphigus vulgaris
Hematopoietic stem cell transplantation (7, 8) Autoimmune diseases unresponsive to immunosuppressive therapy
Haematological diseases (sickle cell anaemia, thalassaemia major, plastic anaemia)
Medical conditions causing POI (9) Altered hypothalamic–pituitary–gonadal axis (10, 11)
Ovarian oophoritis
Benign ovarian tumours
Mosaic Turner's syndrome
Fragile X Mental Retardation 1 (12)
Galactosaemia (13)
Beta-thalassaemia
(14)
Endometriosis (15)
Male genetic disorders Klinefelter's syndrome (6)
Testicular damage (16)
Gender reassignment procedures (17)
Severe body trauma requiring surgical intervention
Note: POI ¼ premature ovarian insufﬁciency.
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Fertility and Sterility®Testicular injury may also result in irreparable damage to
the testicular tissue leading to infertility (16). Salvage, even
in cases of subjectively dead testicle, and FP options can be
offered (25).
Gender reassignment procedures. Removal of testicles or
ovaries destroy the ability to have genetically- related chil-
dren, while feminizing/masculinizing medications used in
gender reassignment procedures may lead to diminished
fertility. It is necessary to discuss and provide counselling
about FP and fertility treatment ‘before starting hormone
therapy or undergoing surgery to remove/alter their repro-
ductive organs’ even at a younger age (26), although there
are ethical concerns (27). Evidence regarding reproductiveTABLE 2
Clinical outcomes from fertility preservation techniques in women.
Author FP technique Women/
Dolmans et al., (18) Embryo cryopreservation 54/Cancer
33 returned/
Oktay et al., (19) Embryo cryopreservation 33/Breast can
18 returned/
Cobo et al., (20) Oocyte vitriﬁcation Ovum donat
Cobo et al., (21) Oocyte vitriﬁcation Delaying chil
non-oncolo
medical co
Donnez et al., (22) Ovarian tissue cryopreservation
Note: FP ¼ fertility preservation; ET ¼ embryo transfer; LBR ¼ live birth rate; CLBR ¼ cumulative liv
Martinez. Update on fertility preservation. Fertil Steril 2017.
VOL. 108 NO. 3 / SEPTEMBER 2017health issues in individuals receiving treatments for gender
dysphoria is scarce. Currently, there are no established tech-
niques for preserving gonadal function in pre-pubertal or pu-
bertal adolescents, who will never develop reproductive
function in their natal sex owing to blockers or cross-
gender hormones.
Delayed Childbearing
Female fertility decreases gradually but signiﬁcantly after age
32 years, and faster after 37 years, which compromises
fertility when delaying childbearing. The term ‘AGE banking’
(oocyte banking for anticipated gamete exhaustion) has been
proposed for oocyte cryopreservation in these cases (28).Indication Outcome
20 ET
22% LBR per ET
nine pregnancies
Four deliveries
cer
55 ET
45% LBR per ET
26 pregnancies
18 deliveries
ion programme 6.5% oocyte-to-baby rate.
CLBR increased with the number of oocytes used
dbearing or
gical
nditions
50% LBR per patient in women%35 years old
22.9% LBR per patient in women >36 years old
N ¼ 111 cases, 32 conceived
29.0% LBR per patient
e birth rate.
409
FIGURE 1
PATIENT SEMEN ANALYSIS TESTICULARBIOPSY
INTRA-OPERATIVE
ANALYSIS
METHOD OF
CRYOPRESERVATION
Pre-Pubertal
Biopsy with NO
intra-operative
analysis
No sperm/
sperm unlikely*
Sperm detected/
Sperm likely*
Immature testis
protocol
Semen Storage
protocol
Immature testis
protocol
+
Mature testis protocol
Biopsy with
intra-operative
analysis
Unable to produce
sperm (eg <12)
Unsuitable for semen
cyropreservation
Oligozoospermia/
Azoospermia
or
Pubertal
Suitable for semen
cyropreservation
Algorithm for the cryopreservation of testicular tissue/sperm in pre-pubertal and adolescent patients at high risk of infertility. Clinical assessment for
puberty should be carried out by a clinician with experience in pubertal assessment. It must be stressed that no clinical parameter can accurately
predict the presence of sperm. The proven treatment option for pubertal and adolescent boys who are considered capable of producing a semen
sample is semen collection and cryopreservation. If sufﬁcient sperm are recovered, the gametes can be banked using commercial glycerol-based
sperm cryomedia. For those young patients who are clinically pre-pubertal and for whom semen cryopreservation is not possible, the fertility
preservation strategy should include collection of a testicular biopsy by an experienced surgeon. The tissue should be cryopreserved with a
protocol optimised for preserving immature germ cells, (immature testis protocol). Patients who are pubertal but are unable to produce a
suitable semen sample may proceed to testicular biopsy, with intra-operative analysis. Techniques for intra-operative analysis may vary between
institutions but should be aimed at identifying tissue containing (or likely to contain) sperm. This should be carried out by an individual with
experience in analysis of testicular tissue (e.g. surgeon, embryologist or andrologist). When sperm are not identiﬁed or deemed unlikely the
tissue should be frozen with the immature testis protocol used for pre-pubertal patients. For patients in whom sperm are identiﬁed or
considered likely to be present, tissue should be split into two portions for storage. One portion should be cryopreserved using the immature
testis preservation protocol, while the second portion should be stored using a protocol aimed at preserving mature sperm cells with glycerol as
the main cryoprotectant. As stated in the text, at present there are several protocols for cryopreservation of immature testicular tissue and there
is no clear evidence at the time of writing to demonstrate which is optimal. Reprinted with permissions from (2).
Martinez. Update on fertility preservation. Fertil Steril 2017.
ASRM PAGESAVAILABLE PROCEDURES FOR FP
Women
Both embryo and oocyte cryopreservation (slow freezing or
vitriﬁcation) are ﬁrst-line FP methods (5) (Fig. 1). However,
oocyte cryopreservation is increasingly preferred (4). Mature
oocyte vitriﬁcation is preferred in post- pubertal women
when gonadotoxic treatment can be delayed to allow
time for controlled ovarian stimulation (COS) (29). Harvesting
of immature oocytes would be an option for patients
unable to undergo COS such as prepubertal girls or women
with aggressive or hormone-sensitive cancers (30). IVM
improves outcomes in breast cancer patients undergoing
COS for FP (31).
Ovarian tissue cryopreservation (OTC) is a COS-
independent experimental technique which also allows
immediate cancer treatment, and is currently the only FP op-
tion in paediatric patients (7) and in hormone-dependent dis-
eases (32). Reimplantation of this tissue either in the pelvic
cavity (orthotopic) or elsewhere (heterotopic) has the potential
of restoring fertility and ovarian hormone secretion. Reim-410plantation of frozen–thawed ovarian tissue in the pelvic cavity
is usually carried out by laparoscopy. The surgical technique is
contingent on the presence (or not) of at least one ovary (33).
Ovarian tissue could also be preserved as an entire ovary
with its vascular pedicle, preventing ischaemic damage
occurring between transplantation and revascularization
(34). Fertility restoration after whole ovary preservation re-
quires retransplantation of the whole organ accompanied
by vascular anastomoses of the blood vessels. Natural fertility
has been fully restored following autotransplantation of
whole ovaries and their supporting vascular pedicle after
slow freezing and thawing in sheep (35). Cryopreservation
of the whole ovary is likely to be more problematic in adult
women due to the increased size of their ovaries, the difﬁculty
of achieving adequate perfusion and penetration of the
cryoprotectants agents through the whole organ, and the
inherently different freezing and thawing optima for the
different cell types in both the ovary and blood vessels (36).
More research is needed before this technique can be trans-
lated into clinical practice.VOL. 108 NO. 3 / SEPTEMBER 2017
Fertility and Sterility®Fertoprotective agents. GnRH analogues/agonists (GnRHa)
may protect follicles from destruction during chemotherapy,
probably by suppression of gonadotrophin levels and reduc-
tion of utero-ovarian perfusion (37). These agents have long
been used for the prevention of ovarian damage, despite their
debatable efﬁcacy. Two meta-analyses of randomised trials
using GnRHa have found an overall signiﬁcantly reduced
risk of POI in young breast cancer patients (38, 39). This
protective effect of GnRHa is less clear in other cancer
patients (ovarian) or not present at all, as in young patients
with lymphoma (40). Still, the quality of evidence is
relatively low given the number of women included,
relatively short term follow-up hitherto and signiﬁcant het-
erogeneity. Further high quality studies are needed to study
the long-term effects of GnRHa on the prevention of POI.Men
Sperm cryopreservation is the only established FP method in
adult and adolescent males. Alternatives to the procurement
of semen samples by masturbation include assisted ejacula-
tion methods such as penile vibratory stimulation or electro-
ejaculation. An algorithm for sperm and testicular tissue
cryopreservation in prepubertal boys and adolescent
males at high risk of fertility loss has been recently recom-
mended (2) (Fig. 1).RESULTS OF ART AFTER FP
Women
As a well-established technology, embryo cryopreservation
has high pregnancy success rates (41). However, outcomes
in cancer patients are scarce. Table 2 summarizes recently re-
ported clinical outcomes from FP techniques in women. A
similar live birth rate (LBR) per patient among women with
cancer undergoing IVF and embryo cryopreservation, and cu-
mulative live birth rate (CLBR) to that achieved with fresh em-
bryos in non-cancer patients has been reported (18) (Table 2).
Success rates associated with oocyte vitriﬁcation are superior
to slow freezing (42). Among women undergoing oocyte vitri-
ﬁcation because of age or because of non-oncological medi-
cal conditions, a LBR per patient of 50% among women aged
%35 years was found, and of 22.9% among those aged
>36 years after the transfer of embryos obtained from vitri-
ﬁed oocytes. CLBR was higher and increased faster among
younger women (21) (Table 2). These success rates are compa-
rable to those achieved with fresh oocytes (43, 44). Outcomes
after oocyte vitriﬁcation among female cancer patients are
scarce. Martinez et al., (36) reported fertilization rates up to
76.6% and a mean (SD) number of embryos transferred of
1.8–0.7 among 11 women with cancer, four of whom gave
birth at term with no negative perinatal outcomes. Alvarez
et al., (45) ﬁrst reported a successful birth in a woman with
invasive ovarian cancer.
Despite being considered an experimental technique,
both restoration of ovarian function and spontaneous preg-
nancies after ART have been reported after orthotopic trans-
plantation of cryopreserved ovarian tissue (46). Only one case
of a live birth after heterotopic transplantation has been re-VOL. 108 NO. 3 / SEPTEMBER 2017ported up to 2013 (47). Recently, Demestree et al. have re-
ported the ﬁrst live birth following re- grafting of ovarian
tissue that had been cryopreserved during childhood in a
13-year old girl undergoing HSCT (48). A large series of 60
live births after transplantation of cryopreserved ovarian tis-
sue (OTT) has been reported, showing that by repeating the
procedure, ovarian activity can be restored for more than
11 years (49). In a series of 111 cases, the conception rate after
OTT was 29%. Two women delivered three babies each,
proving the efﬁcacy of the technique, as well as the possibility
of conceiving naturally several times after only one trans-
plantation procedure (22, 50). Although it is impossible to
provide a ﬁxed success rate for OTT as long as it remains
active (51), given these encouraging results, ovarian cortex
transplantation is proposed as an open clinical application
(22).Men
Success rates of semen cryopreservation have greatly
increased with advances in ICSI, with pregnancy rates of up
to 57% (2). With ICSI (52), reported a LBR of 62.1% in a cohort
of 272 men with cancer, which was signiﬁcantly higher than
that of the comparative normospermic non-cancer popula-
tion. To date, no clinical outcomes have been reported with
other FP techniques.FUTURE PERSPECTIVES
Figure 2 summarizes all FP techniques that are currently un-
der study.Women
Activation of ovarian follicles. Cryopreserved ovarian tissue
from prepuberal patients and patients at risk of primary POI
contains immature primordial follicles that must be activated
in order to start developing. Activation of primordial follicles
can be induced in vivo by mechanically interrupting the Hip-
po signalling pathway (by ovarian fragmentation, drilling,
laser) (53). Follicle activation may also be achieved in vitro
before autotransplantation by acting on the PI3K-PTEN-
AKT-FOXO3 pathway [phosphatidylinositol 3-kinase (PI3K)
activators and phosphatase and tensin homologue enzyme
(PTEN) inhibitors, protein kinase B (AKT) stimulators, tran-
scriptional factor forkhead box O3 (FOXO3)] which regulates
primordial follicle dormancy at oocyte level (53). Using this
double approach in women with POI (54), found rapid follicle
growth after grafting ovarian tissue back to patients, obtain-
ing mature eggs. A live birth was achieved after IVF and em-
bryo transfer. In vitro activation protocols are under
development with the aim of increasing the pool of viable
activated follicles available for in vitro growth (IVG) proced-
ures (55).
In vitro follicle culture. Transplantation of cryopreserved tis-
sue carries the risk of re-seeding original cancer cells into the
patient (56, 57). This risk can be minimised by using complete
IVG and maturation of oocytes as the means of fertility
restoration (58).411
FIGURE 2
Fertility preservation techniques in women. Experimental procedures are indicated in discontinuous boxes, while established ones (i.e. those proven
to restore fertility, with live births reported) are indicated in shaded boxes. Vitriﬁed-thawed oocytes can be fertilized by IVF/ICSI for embryo transfer.
Immature oocytes can be matured in vitro (IVM) for IVF/ICSI. Research is undergoing on the potential use of oogonial stem cells to repopulate
follicle-depleted ovaries or differentiating follicle somatic cells and oocytes from embryonic stem cells or induced pluripotent stem cells to
assemble de novo follicles for transplantation or IVM and IVF/ICSI. *Cryopreserved. OT ¼ ovarian tissue.
Martinez. Update on fertility preservation. Fertil Steril 2017.
ASRM PAGESTo date, three-dimensional (3D) culture methods have
proven most successful in supporting the demands of human
follicle activation and IVG as these approaches are best able to
mimick the in vivo ovarian growth environment. Several
multi-step culture systems have succeeded in culturing hu-
man follicles (59, 60, 61). Critically, all IVG systems used
for fertility restoration for FP patients must start with the in
situ culture of primordial follicles from cryopreserved tissue.
The recent production of meiotically competent metaphase
II non-human primate and human oocytes following IVG of
freshly isolated secondary follicles (62, 63) is encouraging.
However, considerable further research effort is needed to
conﬁrm the safety and efﬁcacy of oocytes derived following
extended IVG and maturation of human oocytes from
cryopreserved tissue before this technology can used to
restore fertility in FP patients (64).
Artiﬁcial ovaries. An alternative to the in vitro culture of pri-
mordial follicles is their development into an engineered ‘arti-
ﬁcial ovary’, consisting of isolated preantral follicles along
with other ovarian cells assembled in a structure- 3D matrix,
or scaffold, which allows follicles to grow and develop in an
ovarian-like environment (65, 66). Once transplanted to the
patient, this ‘artiﬁcial ovary’ would potentially restore
fertility and endocrine function (32).412New fertoprotective agents. The most recent theory of
chemotherapy-induced follicle loss suggests that, simulta-
neously with large follicle apoptosis, chemotherapy also trig-
gers activation of dormant follicle growth. Current research
focuses thus on both agents with anti-apoptotic properties
(imatinib, sphingosine-1-phosphate, thyroid hormone T3,
granulocyte colony- stimulating factor and tamoxifen) that
have been shown to reduce follicle loss in animal models
and on agents that also prevent follicle activation such as
AS101, an immune modulator that acts on the PI3K/PTEN/
AKT follicle activation pathway (67), and the anti-Mullerian
hormone (68). Clinical applicability of these agents depends
not only on their fertoprotective capacity, but also on their
potential interaction with cancer treatments.Men
The risk of reintroducing malignant cells via the graft might
be overcome by in vitro spermatogenesis. SSCs (whole testic-
ular biopsy or isolated SSCs) are cultured in 3D systems that
resemble the in vivo situation (2). The genetic stability of a
long-term culture of human SSCs from two prostate cancer
patients has been reported, although changes in the methyl-
ation status were observed (69). The consequences of theseVOL. 108 NO. 3 / SEPTEMBER 2017
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or sperm. However, the population of PGC is scarce and de-
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sources of gametes (70).
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The Expert Working Group made the following
recommendations:
 Several oncological and non-oncological diseases may
affect current or future fertility, either due to the disease it-
self or to gonadotoxic treatment, and need an adequate FP
approach. These patients should be counselled regarding
potential fertility loss and should be referred to fertility spe-
cialists to discuss options for FP and current results.
 Womenwishing to postpone maternity and transgender in-
dividuals before starting hormone therapy or undergoing
surgery to remove/alter their reproductive organs should
also be counselled accordingly.
 Embryo and oocyte cryopreservation are ﬁrst-line FP
methods in postpubertal women. Metaphase II oocyte cryo-
preservation (vitriﬁcation) is the preferred option.
 Cumulative evidence for restoration of ovarian function
and spontaneous pregnancies after ART following ortho-
topic transplantation of cryopreserved ovarian tissue sup-
ports its future consideration as an open clinical
application.
 Semen cryopreservation is the only established FP tech-
nique in men.
 Testicular tissue cryopreservation should be recommended
in pre- pubertal boys even though fertility restoration stra-
tegies by autotransplantation of cryopreserved testicular
tissue have not yet been tested for safe clinical use in
humans.
 The establishment of international registries on the short-
and long- term outcomes of FP techniques is strongly
recommended.VOL. 108 NO. 3 / SEPTEMBER 2017ACKNOWLEDGMENTS
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Fertility and Sterility®INTRODUCTION
Reproductive capacity may be seriously affected by age,
different conditions, including genetic syndromes, and also
by treatments, especially those with gonadal toxicity. Fertility
preservation (FP) is a fundamental issue for individuals of
reproductive age, both male and female, or prepubescent
boys and girls whose future fertility may be compromised.
There is general consensus on the need to provide counselling
about currently available FP options to all individuals
wishing to preserve their fertility. Timely referral to a fertility
specialist for informed FP decisions becomes essential.
Several techniques for FP are nowadays well established
while others are still considered experimental. These tech-
niques have been the subject of continuous review by experts
with the aim of providing physicians involved in FP with up-
to-date knowledge and counselling. Given the particular na-
ture of FP, recommendations are largely based on cohort
studies, case series, small non-randomized clinical trials, or
case reports, which further makes FP a challenging but rather
controversial ﬁeld.
Reviews have been mostly focused on cancer, which is
probably the main indication for FP given its high incidence
and impact on reproductive health (1–6). However, the need
for FP in other pathologic situations, either due to the disease
itself or to gonadotoxic treatment, and even in non-medical
indications, is on the rise. Moreover, new perspectives to
tackle FP are being developed, and evidence about the results
of spontaneous pregnancy and ART after current FP proced-
ures is growing, which may further help clinicians provide
adequate counselling. With the aim of reviewing all these as-
pects and drawing recommendations, an international
meeting with representatives from expert scientiﬁc societies
involved in FP was held in Barcelona (Spain) in June 2015.
This paper summarizes the topics debated, with a special focus
on indications for FP, current outcomes and future perspec-
tives. A condensed version of this summary has been included
in the print issue of Fertility and Sterility.
MATERIALS AND METHODS
Twenty international FP experts belonging to the American
Society of Reproductive Medicine (ASRM), ESHRE and the In-
ternational Society of Fertility Preservation (ISFP) attended
the meeting. Experts conducted a review of the literature
and evidence presented in scientiﬁc meetings up to June
2015 to be discussed at the meeting. At the time this manu-
script was being written, new evidence considered relevant
for the debated topics was published, and has consequently
been included. Given the lack of studies in large cohorts or
with a randomized design, the quality of evidence
according to the European Society for Medical Oncology Clin-
ical Practice Guidelines for fertility preservation in cancer pa-
tients (3) for most of the evidence reviewed was three or
below.
INDICATIONS FOR FP
Cancer
Many forms of cancer are associated with impaired semen
quality or ovarian function at the time of cancer diagnosis.VOL. 108 NO. 3 / SEPTEMBER 2017However, the main effect on fertility arises from commonly
used treatments such as chemotherapy with alkylating agents
and pelvic radiation that present well-known gonadotoxic
side effects. Gonadal failure resulting from these treatments
may affect different aspects of reproductive health, including
pubertal development, hormone production, and sexual func-
tion in adults (6, 7). The fact that more than 80% of children
and adolescents with cancer become long-term survivors (8)
has raised an increased interest in the long-term effects of
cancer treatment on fertility.
Male. Spermatogonia are especially sensitive to chemo-
therapy and radiotherapy. The effect, which is dose-
dependent, may not be permanent if the spermatogonial
stem cell (SSC) population is not fully depleted (6). Data about
the impact of recent biological or targeted cancer therapies on
male fertility are limited (4). For most of these therapies, the
effects seem to be mild, mostly involving reproductive endo-
crinology (9). Finally, surgical pelvic interventions for malig-
nant or benign disease may affect the anatomy or normal
functioning of reproductive organs (10).
Female. Chemotherapy and radiotherapy may induce pre-
mature ovarian insufﬁciency (POI) in women (11). Ovarian
damage is drug- and dose-dependent and increases as the
patient ages (1). Radiotherapy may also affect the uterus,
leading to reduced vascularity, myometrium damage
(ﬁbrosis) and hormone-dependent insufﬁciency (5). Recent
evidence in female survivors of childhood cancer shows
that chemotherapy without radiotherapy to the brain or
the pelvis has few effects on future pregnancy or live
births (12). In any case, FP should be considered prior
to chemotherapy to maximize future reproductive poten-
tial. Data about the impact of recent biological or targeted
cancer female fertility therapies is also limited except for
bevacizumab, with a 34% rate of POI reported (4). Fertility
may also be impaired by surgical removal or damage to
reproductive organs.Non-oncological Medical Indications
FP options should also be discussed with adult and younger
women and men affected by several non-oncological medical
conditions. Non- oncological systemic diseases, such as hae-
matological and autoimmune conditions, usually require
chemotherapy or radiotherapy, especially for those in need
of a bone marrow or haematopoietic stem cell transplantation
(HSCT) (11). In other conditions reproductive function may be
compromised by genetic causes or by surgical interventions.
Finally, FP may be offered to patients at high risk of fertility
loss as a result of severe body trauma requiring surgical inter-
vention. Table 1 summarizes the most common non-
oncological conditions requiring FP.
Autoimmune diseases. Table 1 summarizes autoimmune
diseases reported to beneﬁt from immunosuppressive therapy
with alkylating agents (cyclophosphamide) (11, 13). POI in
these women is also affected by disease duration and presence
of anti-Ro and anti-U1RNP (ribonucleoprotein) antibodies
(17). Continuous POI in women with chronic autoimmune
diseases also increases the risk of hypoestrogenism-related415.e2
TABLE 1
Non-oncological conditions requiring fertility preservation.
Indication Disease
Autoimmune diseases (11, 13) Systemic lupus erythematosus (SLE)
Behcet's disease
Churg-Strauss syndrome (eosinophilic granulomatosis)
Steroid resistant glomerulonephritis
Granulomatosis with polyangiitis (formerly Wegener's granulomatosis)
Inﬂammatory bowel diseases
Rheumatoid arthritis
Pemphigus vulgaris
Hematopoietic stem cell transplantation (11, 14) Autoimmune diseases unresponsive to immunosuppressive therapy
Haematological diseases (sickle cell anaemia, thalassaemia major, plastic anaemia)
Medical conditions causing POI (15) Altered hypothalamic–pituitary–gonadal axis (16, 17)
Ovarian oophoritis
Benign ovarian tumours
Mosaic Turner's syndrome
Fragile X Mental Retardation 1 (18) Galactosemia (19)
Beta-thalassaemia (20)
Endometriosis (21)
Male genetic disorders Klinefelter's syndrome (13)
Testicular damage (22)
Gender reassignment procedures (23)
Severe body trauma requiring surgical intervention
Note: POI ¼ premature ovarian insufﬁciency.
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ASRM PAGEScomorbidities (including cardiovascular disease and osteopo-
rosis) (24). Males with systemic lupus erythematosus show a
high frequency of testicular Sertoli cell dysfunction associ-
ated with semen abnormalities (25). New treatment ap-
proaches are changing the prognosis of patients with
autoimmune diseases, although information about toxicity
for reproduction is still limited.
Hematopoietic stem cell transplantation. HSCT (autologous
or allogeneic) has been an important therapeutic tool for some
oncological and non-oncological systemic diseases. Patients
undergoing HSCT are at particularly high risk of developing
ovarian (64–85%) or testicular (50–90%) failure since
aggressive chemotherapy and radiotherapy is needed to
destroy pre-existing bone marrow (14). The most common
non-oncological diseases beneﬁting from HSTC are
autoimmune diseases that are unresponsive to immuno-
suppressive therapy or benign haematological diseases
(Table 1) (11).
Medical conditions causing POI. POI may also result from
several other causes, including an altered hypothalamic–
pituitary–gonadal axis, ovarian oophoritis, benign ovarian
tumours, either due to their extensive or progressive nature,
or bilateral adnexectomy (16, 17). POI is also common in
Turner's syndrome. However, FP may not be feasible for
most patients with this disease since by the time they reach
puberty their primordial follicle reserve may already be
depleted. FP may only be offered to young patients with
mosaic Turner's syndrome after careful consideration of
increased pregnancy-associated risks (15, 26).
Other conditions associated with POI include FMR1 gene
mutations (Fragile X Mental Retardation 1) as a result of
premature ovarian aging (18), classic galactosemia (19) or
beta-thalassaemia in female patients who suffer from415.e3hypogonadotrophic hypogonadism associated with amenor-
rhoea, anovulation and infertility (20).
It is well documented that women with endometriosis are
at increased risk of POI and that about half of them will expe-
rience infertility (21). The causal relationship between endo-
metriosis and infertility is unclear (27). FP may be of
interest for reproductive-age women at risk of impaired
fertility due to progression or surgical treatment of this con-
dition (28). Nevertheless, some authors restrict FP to women
with bilateral unoperated endometriomas and those with pre-
vious unilateral endometrioma removal requiring surgery for
a contralateral recurrence (21).
Male genetic disorders and testicular tissue damage. Kline-
felter's syndrome is the most common sex chromosomal dis-
order in humans. This syndrome causes hypogonadism and
azoospermia in >90% cases (13, 22). Testicular injury may
also result in irreparable damage to the testicular tissue lead-
ing to infertility (22). A recent study has highlighted the rele-
vance of attempting salvage, even in cases of subjectively
dead testicle, and to offer the patient FP options (29).
Gender reassignment procedures. Removal of testicles or
ovaries destroys the ability to have genetically- related chil-
dren, while feminizing/masculinizing medications used in
gender reassignment procedures may lead to diminished
fertility (23). The World Professional Association for Trans-
gender Health has emphasized the need to discuss and provide
counselling about FP and fertility treatment ‘before starting
hormone therapy or undergoing surgery to remove/alter their
reproductive organs’ even at a younger age (30). Further, the
Endocrine Society recommends providing counsel about FP
‘prior to initiation of puberty suppression in adolescents
and before treatment with sex hormones of the desired sex
in both adolescents and adults’ (31). Evidence regardingVOL. 108 NO. 3 / SEPTEMBER 2017
Fertility and Sterility®reproductive health issues in individuals receiving treatments
for gender dysphoria is scarce. Currently, there are no
established techniques for preserving gonadal function in
pre- pubertal or pubertal adolescents, who will never develop
reproductive function in their natal sex owing to blockers or
cross-gender hormones (30). There is an ongoing ethical
debate on whether FP should or should not be offered to
transgender individuals (32).Delayed Childbearing
Female fertility decreases gradually but signiﬁcantly after age
32 years, and faster after 37 years, which compromises
fertility when delaying childbearing (33). This is important,
since an increasing proportion of couples in developed coun-
tries choose to have children later in life (R35 years). Given
that delaying childbearing is considered a non-medical indi-
cation for FP, the term ‘AGE banking’ (oocyte banking for
anticipated gamete exhaustion) has been proposed for oocyte
cryopreservation in these cases (34).AVAILABLE PROCEDURES FOR FP
The most recent practice guidelines issued for cancer patients
by the ASRM (1) and the American Society of Clinical
Oncology (4) provide an exhaustive review of all evidence
supporting currently available FP procedures, which may
be adaptable to all scenarios where fertility may be
compromised.Women
Both, embryo and oocyte cryopreservation (slow freezing or
vitriﬁcation) are ﬁrst-line FP methods (Fig. 1). However,
oocyte cryopreservation is increasingly preferred in adoles-
cent girls or young women without a life partner given that
it overcomes religious, ethical or practical issues related to
embryo storage (4, 35). Mature oocyte vitriﬁcation is
preferred in post-pubertal women when gonadotoxic treat-
ment can be delayed to allow time for controlled ovarian
stimulation (COS) (36). Harvesting of immature oocytes by
aspiration would be an option for patients unable to undergo
COS such as pre-pubertal girls, women with aggressive or
hormone- sensitive cancers, or those with polycystic ovary
syndrome (37). The beneﬁts of adding tamoxifen or letrolo-
zole to COS regimens administered to women with breast
cancer are still unclear (38). IVM has been shown to
improve outcomes in breast cancer patients undergoing COS
for FP (39).
Ovarian tissue cryopreservation (OTC) is a COS-
independent experimental technique which also allows im-
mediate cancer treatment, and is currently the only FP option
in paediatric patients (11) and in hormone-dependent diseases
(37). Reimplantation of this tissue either in the pelvic cavity
(orthotopic) or elsewhere (heterotopic) has the potential of
restoring fertility and ovarian hormone secretion. Reimplan-
tation of frozen–thawed ovarian tissue in the pelvic cavity is
usually carried out by laparoscopy, but the surgical technique
is contingent on the presence (or not) of at least one ovary. If
an ovary is present, the remaining atrophic cortex is removedVOL. 108 NO. 3 / SEPTEMBER 2017using scissors, thereby creating a grafting bed onto which the
thawed ovarian fragments are placed. If no ovaries remain,
the ovarian pieces are placed in a peritoneal window created
in the peritoneum of the broad ligament, in an area where
retroperitoneal capillaries are visible (40).
Ovarian tissue could also be preserved as an entire ovary
with its vascular pedicle, preventing ischaemic damage occur-
ring between transplantation and revascularization (41).
Fertility restoration after whole ovary preservation requires
retransplantation of the whole organ accompanied by
vascular anastomoses of the blood vessels. However, although
recent evidence from large animals, such as sheep, suggests
that natural fertility can be fully restored following autotrans-
plantation of whole ovaries and their supporting vascular
pedicle after slow freezing and thawing (42, 43), cryopreserva-
tion of the whole ovary is likely to be more problematic in
adult women owing to the increased size of their ovaries, the
difﬁculty of achieving adequate perfusion and penetration
of the cryoprotectants agents through the whole organ, and
the inherently different freezing and thawing optima for the
different cell types in both the ovary and blood vessels.
Although several methods have been developed to help over-
come these barriers (42–45), more research is needed before
this technique can be translated into clinical practice.
Fertoprotective agents. GnRH analogues/agonists (GnRHa)
may protect follicles from destruction during chemotherapy,
probably by suppression of gonadotrophin levels and reduc-
tion of utero-ovarian perfusion (46). These agents have long
been used for the prevention of ovarian damage, despite their
efﬁcacy being a subject of debate owing to inconsistent
results from randomized trials using GnRHa (47–54). Two
meta-analyses of randomized trials have found an overall sig-
niﬁcant reduced risk of POI in young breast cancer patients
(55, 56). GnRHa increased the pregnancy rate and had no
negative impact on prognosis (56). This protective effect was
not as clear in other cancer patients (ovarian and lymphoma)
(55). Recently, no protective effect at all was found in young
patients with lymphoma (57). Still, the quality of evidence is
relatively low given the number of women included, relatively
short-term follow-up hitherto and signiﬁcant heterogeneity.
Further high quality studies are needed to study the (long-
term) effects of GnRHa use on POI.Men
Sperm cryopreservation is the only established FP method in
adult and adolescent males. Alternatives to the procurement
of semen samples by masturbation include assisted ejacula-
tion methods such as penile vibratory stimulation or electro-
ejaculation. A recent paper on the European perspective on
testicular tissue cryopreservation for FP in pre-pubertal and
adolescent boys by the ESHRE Task Force on Fertility Preser-
vation for severe diseases recommends an algorithm for
sperm and testicular tissue cryopreservation in pre-pubertal
boys and adolescent males at high risk of fertility loss (7).
This algorithm includes alternative experimental techniques,
such as testicular sperm extraction (TESE), for patients pre-
senting oligo- or azoospermia at the time of cryopreservation
or those with necrozoospermia or ejaculation disorders, or415.e4
FIGURE 1
PATIENT SEMEN ANALYSIS TESTICULARBIOPSY
INTRA-OPERATIVE
ANALYSIS
METHOD OF
CRYOPRESERVATION
Pre-Pubertal
Biopsy with NO
intra-operative
analysis
No sperm/
sperm unlikely*
Sperm detected/
Sperm likely*
Immature testis
protocol
Semen Storage
protocol
Immature testis
protocol
+
Mature testis protocol
Biopsy with
intra-operative
analysis
Unable to produce
sperm (eg <12)
Unsuitable for semen
cyropreservation
Oligozoospermia/
Azoospermia
or
Pubertal
Suitable for semen
cyropreservation
Algorithm for the cryopreservation of testicular tissue/sperm in pre-pubertal and adolescent patients at high risk of infertility. Clinical assessment for
puberty should be carried out by a clinician with experience in pubertal assessment. It must be stressed that no clinical parameter can accurately
predict the presence of sperm. The proven treatment option for pubertal and adolescent boys who are considered capable of producing a semen
sample is semen collection and cryopreservation. If sufﬁcient sperm are recovered the gametes can be banked using commercial glycerol-based
sperm cryomedia. For those young patients who are clinically pre-pubertal and for whom semen cryopreservation is not possible the fertility
preservation strategy should include collection of a testicular biopsy by an experienced surgeon. The tissue should be cryopreserved with a
protocol optimized for preserving immature germ cells, (immature testis protocol). Patients who are pubertal but are unable to produce a
suitable semen sample may proceed to testicular biopsy, with intra-operative analysis. Techniques for intra-operative analysis may vary between
institutions but should be aimed at identifying tissue containing (or likely to contain) sperm. This should be carried out by an individual with
experience in analysis of testicular tissue (e.g. surgeon, embryologist or andrologist). When sperm are not identiﬁed or deemed unlikely the
tissue should be frozen with the immature testis protocol used for pre-pubertal patients. For patients in whom sperm are identiﬁed or
considered likely to be present, tissue should be split into two portions for storage. One portion should be cryopreserved using the immature
testis preservation protocol, whilst the second portion should be stored using a protocol aimed at preserving mature sperm cells with glycerol
as the main cryoprotectant. As stated in the text at present there are several protocols for cryopreservation of immature testicular tissue and
there is no clear evidence at the time of writing to demonstrate which is optimal. Reprinted with permission from (7).
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ervation when no sperm can be collected (Fig. 1).RESULTS OF ART AFTER FP
Women
As a well-established technology, embryo cryopreservation
has high pregnancy success rates (35). However, outcomes
in cancer patients are scarce. Recently (58), reported a 44%
live birth rate (LBR) per patient among 54 women with cancer
undergoing IVF and embryo cryopreservation, with a cumu-
lative live birth rate (CLBR) similar to that achieved with fresh
embryos in non-cancer patients (Table 2). Similarly, Oktay
et al. reported 18 pregnancies and 25 live births among 33
women with breast cancer, with a LBR of 45% per embryo
transfer (59). Success rates associated with oocyte cryopreser-
vation have signiﬁcantly improved in recent years, with vitri-
ﬁcation success rates being superior to slow freezing (63). A
recent report of the outcomes achieved in oocyte donation
showed a 6.5% oocyte-to-baby rate, with CLBR increasing415.e5with the number of oocytes used (60). A similar report among
women undergoing oocyte vitriﬁcation because of age or
because of non-oncological medical conditions revealed a
LBR per patient of 50% among women aged %35 years,
and of 22.9% among those aged >36 years after the transfer
of embryos obtained from vitriﬁed oocytes. The CLBR was
higher and increased faster among younger women (61) (Ta-
ble 2). It should be noted that these ﬁgures arise from patients
with a good prognosis who are managed by a highly experi-
enced team, and therefore may not be representative of other
FP programmes (64). These success rates are comparable to
those achieved with fresh oocytes (65, 66). Outcomes after
oocyte vitriﬁcation among female cancer patients are scarce.
Martinez et al., (45) reported fertilization rates up to 76.6%
and a mean number of embryos transferred of 1.8  0.7 SD
among 11 women with cancer, four of whom gave birth at
term without negative perinatal outcomes. Alvarez et al.,
(67) ﬁrst reported a successful birth in a woman with invasive
ovarian cancer.
Despite being considered an experimental technique both
restoration of ovarian function and spontaneous pregnanciesVOL. 108 NO. 3 / SEPTEMBER 2017
TABLE 2
Clinical outcomes from fertility preservation techniques in women.
Author FP technique Women/Indication Outcome
Dolmans et al., (58) Embryo cryopreservation 54/Cancer
33 returned/20 ET
22% LBR per ET
Nine pregnancies
Four deliveries
Oktay et al., (59) Embryo cryopreservation 33/Breast cancer
18 returned/55 ET
45% LBR per ET
26 pregnancies
18 deliveries
Cobo et al., (60) Oocyte vitriﬁcation Ovum donation programme 6.5% oocyte-to-baby rate.
CLBR increased with the number of oocytes used
Cobo et al., (61) Oocyte vitriﬁcation Delaying childbearing or
non-oncological
medical conditions
50% LBR per patient in women%35 year old
22.9% LBR per patient in women >36 years old
Donnez et al., (62) Ovarian tissue cryopreservation N ¼ 111 cases, 32 conceived
29.0% LBR per patient
FP ¼ fertility preservation; ET ¼ embryo transfer; LBR ¼ live birth rate; CLBR ¼ cumulative live birth rate.
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of cryopreserved ovarian tissue (68–71). Only one case of a
live birth after heterotopic transplantation has been reported
up to 2013 (72). Recently, Demestree et al. have reported the
ﬁrst live birth following re-grafting of ovarian tissue that
had been cryopreserved during childhood in a 13-year old
girl undergoing HSCT (68). To date, a large series of 60 live
births after transplantation of cryopreserved ovarian tissue
has been reported, also showing that by repeating the proced-
ure ovarian activity can be restored for more than 11 years
(69). In a series of 111 cases, the conception rate was 29%.
Two women delivered three babies each, proving the efﬁcacy
of the technique, as well as the possibility of conceiving
naturally several times after only one transplantation proced-
ure (62, 70). Although it is impossible to provide a ﬁxed suc-
cess rate for transplantation of ovarian tissue as long as it
remains active (73), given these encouraging results, ovarian
cortex transplantation is proposed as an open clinical
application (62).
Men
Success rates of semen cryopreservation have greatly
increased with advances in ART, especially in ICSI, with preg-
nancy rates up to 57% (7). With this technique (74), reported a
LBR of 62.1% in a cohort of 272 men with cancer, which was
signiﬁcantly higher than that of the comparative normosper-
mic non-cancer population. To date, no clinical outcomes
have been reported with other FP techniques.
FUTURE PERSPECTIVES
Figure 2 summarizes all FP techniques that are currently un-
der study.
Women
Activation of ovarian follicles. Cryopreserved ovarian tissue
from prepuberal patients and patients with primary POI con-
tains immature primordial follicles that must be activated in
order to start developing. It has been recently described thatVOL. 108 NO. 3 / SEPTEMBER 2017activation of primordial follicles can be induced in vivo by
mechanically interrupting the Hippo signalling pathway (by
ovarian fragmentation, drilling, laser) (75). Follicle activation
may also be achieved in vitro before autotransplantation by
acting on the PI3K- PTEN-AKT-FOXO3 pathway [phosphati-
dylinositol 3-kinase(PI3K) activators and phosphatase and
tensin homologue enzyme (PTEN) inhibitors, Protein Kinase
B (AKT) stimulators, transcriptional factor forkhead box
O3(FOXO3)] which has been shown to regulate primordial fol-
licle dormancy at oocyte level (75). This pathway has also a
fundamental role in FSH stimulation of granulosa cell differ-
entiation of antral follicles and in oocyte maturation of pre-
ovulatory follicles (75). Using this double approach in
women with POI (76), found rapid follicle growth after graft-
ing ovarian tissue back to patients, obtaining mature eggs. A
live birth was achieved after IVF and embryo transfer. In vitro
activation protocols are under development with the aim of
increasing the pool of viable activated follicles available for
in vitro growth (IVG) procedures (77).
In vitro follicle culture. Transplantation of cryopreserved tis-
sue carries the risk of re-seeding original cancer cells into the
patient, as recently highlighted in a series of recent reviews
and reports (72, 78–83). This risk can be minimized by using
complete IVG and maturation of oocytes as the means of
fertility restoration (84, 85). The goal of complete IVG and
maturation of oocytes is particularly challenging in human
follicles because of the greatly extended developmental
time-frame for follicles and oocytes, and increased size of
ovulatory follicles and mature gametes (86). Furthermore,
recent evidence suggests that the dynamics of the in vivo
and hence in vitro growth environments may differ between
the pre- and post-pubertal human ovary (87).
To date, three-dimensional (3D) culture methods have
proved most successful in supporting the demands of human
follicle activation and IVG, as these approaches are best able
to maintain the morphology of the follicles and preserve crit-
ical cell–cell interactions both between the different cellular
compartments in the follicle and between the follicle and its
surrounding stromal tissue thus better mimicking the415.e6
FIGURE 2
Fertility preservation techniques in women. Experimental procedures are indicated in discontinuous boxes, while established ones (i.e. those proven
to restore fertility, with live births reported) are indicated in shaded boxes. Vitriﬁed-thawed oocytes can be fertilized by IVF/ICSI for embryo transfer.
Immature oocytes can be matured in vitro (IVM) for IVF/ICSI. Research is undergoing on the potential use of oogonial stem cells to repopulate
follicle-depleted ovaries or differentiating follicle somatic cells and oocytes from embryonic stem cells or induced pluripotent stem cells to
assemble de novo follicles for transplantation or IVM and IVF/ICSI. *Cryopreserved. OT ¼ ovarian tissue.
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ture systems have succeeded in culturing human follicles (84,
88–91). Critically, all IVG systems used for fertility restoration
for FP patients must start with the in situ culture of primordial
follicles from cryopreserved tissue. The recent production of
meiotically competent metaphase II non-human primate
and human oocytes following IVG of freshly isolated second-
ary follicles (92, 93) is encouraging. However, whether mature
human oocytes can be obtained from primordial follicles
grown from cryopreserved ovarian tissue using these culture
strategies or whether the oocytes so derived are competent to
complete cytoplasmic and nuclear maturation in a timely
manner is yet to be conﬁrmed. It also remains to be conﬁrmed
whether their genomic imprint establishment and mainte-
nance is normal (94) and whether metaphase II gametes so
produced are healthy and able to undergo fertilization and
support normal early embryonic development until the em-
bryonic genome is activated. Considerable further research
effort is therefore needed to conﬁrm the safety and efﬁcacy
of oocytes derived following extended IVG and the matura-
tion of human oocytes from cryopreserved tissue before this
technology can be used to restore fertility in FP patients.
Artiﬁcial ovaries. An alternative to the in vitro culture of
primordial follicles is their development into an engineered415.e7‘artiﬁcial ovary’, consisting of isolated preantral follicles
along with other ovarian cells assembled in a structure- 3D
matrix, or scaffold, which allow follicles to grow and develop
in an ovarian-like environment (95, 96). Ovarian cells from
fresh medullary tissue have been suggested as the best source
of isolated stromal cells for the artiﬁcial ovary (97). Once
transplanted to the patient, this artiﬁcial ovary would poten-
tially restore fertility and endocrine function (37). Following
this procedure (98), reported the production of estradiol
in vitro by primary ovarian cells of mice seeds into a previ-
ously decellularized ovary. Moreover, when transplanted
into ovariectomized mice, grafts from these cells were able
to initiate puberty.
New fertoprotective agents. The most recent theory of
chemotherapy-induced follicle loss suggests that, simulta-
neously with large follicle apoptosis, chemotherapy also trig-
gers activation of dormant follicle growth. Current research
focuses thus on both agents with anti-apoptotic properties
(imatinib, sphingosine-1-phosphate, thyroid hormone T3,
granulocyte colony- stimulating factor and tamoxifen) that
have been shown to reduce follicle loss in animal models
(37), and on agents that also prevent follicle activation
such as AS101, an immune modulator that acts on the
PI3K/PTEN/AKT follicle activation pathway (99), andVOL. 108 NO. 3 / SEPTEMBER 2017
Fertility and Sterility®anti-Mullerian hormone (100). Clinical applicability of these
agents depends not only on their fertoprotective capacity,
but also on their potential interaction with cancer treatments.Men
In a similar way, the risk of reintroducing malignant cells via
the graft might be overcome by in vitro spermatogenesis. As
per follicle culture, SSCs (whole testicular biopsy or isolated
SSCs) are cultured in 3D systems that resemble the in vivo sit-
uation (7). Recently, Nickkholgh et al. have reported the ge-
netic stability of a long-term culture of human SSCs from
two prostate cancer patients and although changes in the
methylation status were observed, the consequences of these
epigenetic changes on the functionality of the sperm of the
health of the offspring are unknown (101). The fertilizing
ability of in vitro-cultured sperm is to be established before
assessing the clinical value of this technique. Moreover,
fertility restoration strategies by autotransplantation of cryo-
preserved testicular tissue have not yet been tested for safe
clinical use in humans (7).Both Sexes
Artiﬁcial gametes. To date, infertile patients lacking func-
tional oocytes or sperm cannot beneﬁt from currently avail-
able ART unless donor gametes are used. The use of
primordial germ cells (PGC) present in the gonads, such as
SSC, is a promising approach for treating infertility. However,
the population of these cells is scarce and decreases with age.
Pluripotent stem cells (PSC), such as embryonic stem cells or
induced PSC, constitute other potential sources of gametes
(102).
Hayashi and Saitou (103) derived functional PGCs from
PSC potentially able to generate functional oocytes and sperm
(102). Recently (104), have reported the generation of haploid
mouse spermatid-like cells able to produce viable and fertile
offspring. Notwithstanding these advances, a recent critical
review of available evidence in humans and animal models
carried out by the ESHRE Special Interest Group in Stem Cells
concluded that ‘to date there are no proven stem cell-based
means to improve reproductive function, either by producing
functional gametes in vitro, or stimulating the resident stem
cell population in the ovary to elicit de novo oocyte produc-
tion’ (102).SUMMARY
The Expert Working Group made the following
recommendations:
 Several oncological and non-oncological diseases may
affect current or future fertility, either due to the disease
itself or to gonadotoxic treatment, and need an
adequate FP approach. These patients should be coun-
selled regarding potential fertility loss and should be
referred to fertility specialists to discuss options for FP
and current results.
 Womenwishing to postpone maternity and transgender in-
dividuals before starting hormone therapy or undergoingVOL. 108 NO. 3 / SEPTEMBER 2017surgery to remove/alter their reproductive organs, should
also be counselled accordingly.
 Embryo and oocyte cryopreservation are ﬁrst-line FP
methods in post-pubertal women. Metaphase II oocyte
cryopreservation (vitriﬁcation) is the preferred option.
 Cumulative evidence of restoration of ovarian function and
spontaneous pregnancies after ART following orthotopic
transplantation of cryopreserved ovarian tissue supports
its future consideration as an open clinical application.
 Semen cryopreservation is the only established FP tech-
nique in men.
 Testicular tissue cryopreservation should be recommended
in pre- pubertal boys even though fertility restoration stra-
tegies by autotransplantation of cryopreserved testicular
tissue have not yet been tested for safe clinical use in
humans.
 The establishment of international registries on the short-
and long- term outcomes of FP techniques is strongly
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